| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.51 mm | 6.51 mm | 6.51 mm | 6.51 mm | 6.51 mm | 6.51 mm |
| Cash burn (monthly) | 912.67 k | (no burn) | 1.20 mm | 1.15 mm | 912.33 k | 1.04 mm |
| Cash used (since last report) | 3.90 mm | n/a | 5.13 mm | 4.90 mm | 3.90 mm | 4.44 mm |
| Cash remaining | 2.61 mm | n/a | 1.38 mm | 1.61 mm | 2.61 mm | 2.07 mm |
| Runway (months of cash) | 2.9 | n/a | 1.1 | 1.4 | 2.9 | 2.0 |
| 13F holders | Current |
|---|---|
| Total holders | 13 |
| Opened positions | 1 |
| Closed positions | 8 |
| Increased positions | 2 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 203.97 mm |
| Total shares | 4.44 mm |
| Total puts | 41.00 k |
| Total calls | 0.00 |
| Total put/call ratio | Infinity |
| Largest owners | Shares | Value |
|---|---|---|
| Cytovance Biologics | 2.76 mm | $860.00 k |
| DekaBank Deutsche Girozentrale | 1.15 mm | $35.10 mm |
| Alpha Capital Anstalt | 265.23 k | $809.00 k |
| Bristol Investment Fund | 190.00 k | $0.00 |
| BMO Bank of Montreal | 29.87 k | $63.03 mm |
| Geode Capital Management | 15.04 k | $34.45 mm |
| Vanguard | 10.50 k | $24.05 mm |
| WFC Wells Fargo & Company | 10.01 k | $23.12 mm |
| BlackRock | 9.74 k | $22.48 mm |
| Advisor | 12.00 | $28.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Oct 24 | Urban Alan Louis | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 2.11 | 23,335 | 49.24 k | 23,335 |
| 11 Aug 23 | Michael Martin Breen | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 856,218 |
| 11 Aug 23 | Manu Ohri | Common Stock | Other | Acquire J | Yes | No | 0.287 | 200,000 | 57.40 k | 300,000 |
| 11 Aug 23 | Manu Ohri | Common Stock | Other | Dispose J | No | No | 0.287 | 200,000 | 57.40 k | 0 |
| 11 Aug 23 | Manu Ohri | Common Stock | Grant | Acquire A | No | No | 0.287 | 200,000 | 57.40 k | 200,000 |
